BTG3 and metabolic dysfunction-associated steatotic liver disease: Non-alcoholic fatty liver disease plus positive autoantibodies (most common scenario): Nonspecific autoantibodies such as ANA, SMAs are seen as an epiphenomenon in a significant proportion of NAFLD patients.